Weixing Zhao

6PUBLICATIONS
4CO-AUTHORS
Molecular targetsDisease surveillanceCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 05, 2026
Pooled safety profiles of bispecific antibodies targeting PD-1/CTLA-4 or PD-1/VEGF in non-small cell lung cancer: a systematic review and single-arm meta-analysis.

|Jan 29, 2026
Post-marketing safety surveillance of tarlatamab: a real-world pharmacovigilance study based on the FAERS database.

Xiaoni Jin, Weixing Zhao, Yuan Li

|Oct 29, 2025
Efficacy and safety of antibody-drug conjugates in the treatment of non-small cell lung cancer: a systematic review and meta-analysis of prospective clinical trials.

Xiaoni Jin, Weixing Zhao, Bo Li

|Oct 15, 2025
Hepatotoxicity of ALK/ROS1 tyrosine kinase inhibitors in non-small cell lung cancer patients: A pharmacovigilance study based on signal mining and analysis of the FDA adverse event reporting system database.

Weixing Zhao, Xiaoni Jin, Yuan Li

|Apr 14, 2025
Immunotherapy for Limited-Stage Small Cell Lung Cancer: Innovative Treatments and Future Perspectives.

Xiaoni Jin, Weixing Zhao, Guoyuan Li

|Aug 28, 2024
Advances in Predictive Biomarkers for Anti-Angiogenic Therapy in Non-Small Cell Lung Cancer.

Weixing Zhao, Jun Jiang

Pageof 1

Frequent Collaborators

2 joint publications

Xiaoni Jin

2 joint publications

Jun Jiang

1 joint publications

Yuan Li

1 joint publications

Huiyuan Peng